Lothian NHS Board

NHS Lothian Headquarters
Waverley Court
4 East Market Street
Edinburgh
EH8 8BG
www.nhslothian.scot

Date 11 September 2026
Your Ref
Our Ref 11829

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – RESEARCH STUDIES

I write in response to your request for information in relation to research studies.

Question:

- Please provide any recorded information identifying research studies sponsored, hosted, supported, or delivered by your organisation name involving any of the substances listed in the attached spreadsheet.

  For each relevant study, please provide the study title or ID, status, sponsor, department or specialty, and any available public link.

  If no relevant information is held, please confirm this. I am not requesting clinical advice, dosage information, or any patient records.

Answer:
Please see enclosed spreadsheet.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, \you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: https://org.nhslothian.scot/FOI/Pages/default.aspx

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive

No.	Peptide / substance name	Relevant recorded research held?	Current study / research status	Organisation role and local approval status	NHS access / formulary position	Recorded future research plans held?	Study / trial ID or public link	Department / specialty	Response notes	Responding organisation
28	Vasopressin / Desmopressin	Yes	Completed	Host, R&D Approved	Specialist	None	DASH, Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage	Neurology	2019/0026	NHS Lothian
38	Semaglutide	Yes	Completed	Host, R&D Approved	Routine for diabetes specialist for obesity	None	PIONEER 6, A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes	Diabetology	2016/0190C	NHS Lothian
38	Semaglutide	Yes	Completed	Host, R&D Approved	Routine for diabetes specialist for obesity	None	PIONEER 5, Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment. A 26-week randomised, double-blind, placebo-controlled trial	Diabetology	2016/0203C	NHS Lothian
38	Semaglutide	Yes	Completed	Host, R&D Approved	Routine for diabetes specialist for obesity	None	NASH-4296, Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.A 72-week randomised, double-blind, placebo-controlled, six-armed parallel group, multi-centre, multinational trial	Hepatology	2016/0300C	NHS Lothian
38	Semaglutide	Yes	Completed	Host, R&D Approved	Routine for diabetes specialist for obesity	None	FLOW, Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease	Diabetology	2019/0067C	NHS Lothian
38	Semaglutide	Yes	Completed	Host, R&D Approved	Routine for diabetes specialist for obesity	None	SOUL, Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes	Diabetology	2019/0139C	NHS Lothian
38	Semaglutide	Yes	Completed	Host, R&D Approved	Routine for diabetes specialist for obesity	None	EVOKE, A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease	Old Age Psychiatry	2021/0183C	NHS Lothian
38	Semaglutide	Yes	Completed	Host, R&D Approved	Routine for diabetes specialist for obesity	None	EVOKE plus, A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease	Old Age Psychiatry	2021/0184C	NHS Lothian
38	Semaglutide	Yes	Active, not recruiting	Host, R&D Approved	Routine for diabetes specialist for obesity	None	REDEFINE 3, The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease	Endocrinology	2024/0013C	NHS Lothian
38	Semaglutide	Yes	Recruiting	Host, R&D Approved	Routine for diabetes specialist for obesity	None	Eluminate-2, A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus	Endocrinology	2026/0141C	NHS Lothian
40	Retatrutide	Yes	Active, not recruiting	Host, R&D Approved	Research-only	None	TRANSCEND-T2D-3, A Phase 3, Randomized, Multicenter, Double-blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared with Placebo in Adult Participants with Type 2 Diabetes, Moderate or Severe Renal Impairment with Inadequate Glycemic Control on Basal Insulin with or without Metformin and/or SGLT2 inhibitor	Diabetology	2024/0134C	NHS Lothian
44	Insulin icodec	Yes	Completed	Host, R&D Approved	Research-only	None	ONWARDS 1, A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulinglargine 100 units/mL, both in combination with non-insulin anti-diabetic treatment, in insulin naïve subjects with type2 diabetes	Diabetology	2020/0195C	NHS Lothian

44	Insulin icodec	Yes	Completed	Host, R&D Approved	Research-only	None	ONWARDS 6, Efficacy and safety of once weekly insulin icodec compared to once daily insulin degludec 100 units/mL, both incombination with insulin aspart, in adults with type 1 diabetes. A 26-week, randomised, multicentre, open-label, active-controlled, parallel group, two armed, treat-to-target trial investigating the effect on glycaemic control and safety of treatment with once weekly insulin icodec compared to once daily insulin degludec, both in combination with insulin aspart in adults with type 1 diabetes, with a 26-week extension investigating long term safety	Diabetology	2021/0125C	NHS Lothian